CDSCO Approves India's First Indigenous Dengue Vaccine With 80% Efficacy

The Central Drugs Standard Control Organization (CDSCO) has officially granted approval for a new, indigenously developed vaccine targeting dengue fever. This landmark regulatory clearance marks a monumental step forward in India's long-standing battle against vector-borne diseases, which place an immense seasonal burden on the country's healthcare infrastructure and public hospitals.

Rigorous clinical trials have demonstrated that the newly approved vaccine is 80% effective in preventing severe forms of dengue fever. This high level of efficacy is expected to dramatically reduce hospitalization rates and mortality associated with severe dengue infections, particularly during the monsoon seasons when outbreaks typically peak across major urban and rural clusters.

Following this regulatory milestone, manufacturing and distribution networks are being prepared for a nationwide rollout. The indigenous vaccine is projected to be available for public use by early 2027. This timeline allows health authorities to coordinate immunization strategies and ensure affordable access to the vaccine across vulnerable populations nationwide.